Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 46.82% | 47.94% | 62.76% | 74.43% | 87.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.15% | 25.19% | 36.79% | 44.70% | 61.80% |
| Operating Income | -22.21% | -25.19% | -36.79% | -44.70% | -61.80% |
| Income Before Tax | -17.19% | -17.60% | -30.68% | -40.36% | -59.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.19% | -17.60% | -30.68% | -40.36% | -59.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.19% | -17.60% | -30.68% | -40.36% | -59.52% |
| EBIT | -22.21% | -25.19% | -36.79% | -44.70% | -61.80% |
| EBITDA | -21.95% | -24.97% | -36.64% | -44.60% | -61.82% |
| EPS Basic | 1.72% | 5.81% | -6.87% | -21.67% | -45.94% |
| Normalized Basic EPS | 1.72% | 5.81% | -6.86% | -21.66% | -45.94% |
| EPS Diluted | 1.72% | 5.81% | -6.87% | -21.67% | -45.94% |
| Normalized Diluted EPS | 1.72% | 5.81% | -6.86% | -21.66% | -45.94% |
| Average Basic Shares Outstanding | 18.52% | 25.01% | 22.84% | 16.37% | 9.89% |
| Average Diluted Shares Outstanding | 18.52% | 25.01% | 22.84% | 16.37% | 9.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |